Abstract:Numerous peptides inhibit the entry of enveloped viruses into cells. Some of these peptides have been shown to inhibit multiple unrelated viruses. We have suggested that such broad-spectrum antiviral peptides share a property called interfacial activity; they are somewhat hydrophobic and amphipathic, with a propensity to interact with the interfacial zones of lipid bilayer membranes. In this study, we further tested the hypothesis that such interfacial activity is a correlate of broad-spectrum antiviral activity. In this study, several families of peptides, selected for the ability to partition into and disrupt membrane integrity but with no known antiviral activity, were tested for the ability to inhibit multiple diverse enveloped viruses. These include Lassa pseudovirus, influenza virus, dengue virus type 2, herpes simplex virus 1, and nonenveloped human adenovirus 5. Various families of interfacially active peptides caused potent inhibition of all enveloped viruses tested at low and submicromolar concentrations, well below the range in which they are toxic to mammalian cells. These membrane-active peptides block uptake and fusion with the host cell by rapidly and directly interacting with virions, destabilizing the viral envelope, and driving virus aggregation and/or intervirion envelope fusion. We speculate that the molecular characteristics shared by these peptides can be exploited to enable the design, optimization, or molecular evolution of novel broad-spectrum antiviral therapeutics.IMPORTANCE New classes of antiviral drugs are needed to treat the ever-changing viral disease landscape. Current antiviral drugs treat only a small number of viral diseases, leaving many patients with established or emerging infections to be treated solely with supportive care. Recent antiviral peptide research has produced numerous membrane-interacting peptides that inhibit diverse enveloped viruses in vitro and in vivo Peptide therapeutics are becoming more common, with over 60 FDA-approved peptides for clinical use. Included in this class of therapeutics is enfuvirtide, a 36-residue peptide drug that inhibits HIV entry/fusion. Due to their broad-spectrum mechanism of action and enormous potential sequence diversity, peptides that inhibit virus entry could potentially fulfill the need for new antiviral therapeutics; however, a better understanding of their mechanism is needed for the optimization or evolution of sequence design to combat the wide landscape of viral disease.

In vitro and in vivo broad antiviral activity of peptides homologous to fusion glycoproteins of Newcastle disease virus and Marek's disease virus

Characterisation and Evaluation of Antiviral Recombinant Peptides Based on the Heptad Repeat Regions of NDV and IBV Fusion Glycoproteins

Structural characteristics and antiviral activity of multiple peptides derived from MDV glycoproteins B and H

Roles of the highly conserved amino acids in the globular head and stalk region of the Newcastle disease virus HN protein in the membrane fusion process.

Interaction Domain of Glycoproteins Gb and Gh of Marek's Disease Virus and Identification of an Antiviral Peptide with Dual Functions

A Cholesterol Tag at the N Terminus of the Relatively Broad-Spectrum Fusion Inhibitory Peptide Targets an Earlier Stage of Fusion Glycoprotein Activation and Increases the Peptide's Antiviral Potency in Vivo

Construction of a Camelid VHH Yeast Two-Hybrid Library and the Selection of VHH Against Haemagglutinin-Neuraminidase Protein of the Newcastle Disease Virus.

Prokaryotic Expression of Structural Domains of the Newcastle Disease Virus Hemagglutinin-Neuraminidase

Broad-Spectrum Antiviral Entry Inhibition by Interfacially Active Peptides

Prokaryotic expression of structural domains of the Newcastle disease virus fusion protein and analyses of their antigenic epitopes

Structure and Function Study of Paramyxovirus Fusion Protein Heptad Repeat Peptides

Assembly and Immunological Properties of a Bivalent Virus-Like Particle (VLP) for Avian Influenza and Newcastle Disease

Recombinant Infectious Bursal Disease Virus Expressing Newcastle Disease Virus (NDV) Neutralizing Epitope Confers Partial Protection Against Virulent NDV Challenge in Chickens.

Multi-Epitopic Peptide Vaccine Against Newcastle Disease Virus: Molecular Dynamics Simulation and Experimental Validation

Evaluation of Fusion Protein Cleavage Site Sequences of Newcastle Disease Virus in Genotype Matched Vaccines

Computational Exploration and Molecular Dynamic Simulation for the Discovery of Antiviral Agents Targeting Newcastle Disease Virus

Recombinant Marek's disease virus type 1 provides full protection against H9N2 influenza A virus in chickens

Exploring the Efficacy of Peptides and Mimics against Influenza A Virus, Adenovirus, and Murine Norovirus

Chimeric Newcastle Disease Virus-like Particles Containing DC-Binding Peptide-Fused Haemagglutinin Protect Chickens from Virulent Newcastle Disease Virus and H9N2 Avian Influenza Virus Challenge

Screening and Mechanistic Study of Key Sites of the Hemagglutinin-Neuraminidase Protein Related to the Virulence of Newcastle Disease Virus

A Novel Recombinant Attenuated Newcastle Disease Virus Expressing H9 Subtype Hemagglutinin Protected Chickens from Challenge by Genotype VII Virulent Newcastle Disease Virus and H9N2 Avian Influenza Virus.